Asprosin levels in patients with type 2 diabetes mellitus, metabolic syndrome and obesity: A systematic review and meta-analysis

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews Pub Date : 2024-07-01 DOI:10.1016/j.dsx.2024.103095

Juan R. Ulloque-Badaracco , Ali Al-kassab-Córdova , Enrique A. Hernandez-Bustamante , Esteban A. Alarcon-Braga , Pamela Robles-Valcarcel , Miguel A. Huayta-Cortez , Juan C. Cabrera Guzmán , Rosa A. Seminario-Amez , Vicente A. Benites-Zapata

{"title":"Asprosin levels in patients with type 2 diabetes mellitus, metabolic syndrome and obesity: A systematic review and meta-analysis","authors":"Juan R. Ulloque-Badaracco , Ali Al-kassab-Córdova , Enrique A. Hernandez-Bustamante , Esteban A. Alarcon-Braga , Pamela Robles-Valcarcel , Miguel A. Huayta-Cortez , Juan C. Cabrera Guzmán , Rosa A. Seminario-Amez , Vicente A. Benites-Zapata","doi":"10.1016/j.dsx.2024.103095","DOIUrl":null,"url":null,"abstract":"<div><h3>Background & aims</h3><p>Asprosin is a promising candidate for novel treatments for metabolic–endocrine disorders. The objective of this systematic review and meta-analysis was to consolidate the existing evidence regarding asprosin levels in patients diagnosed with type 2 diabetes (T2D), metabolic syndrome (MetS), and obesity.</p></div><div><h3>Methods</h3><p>Scopus, Embase, PubMed, Ovid/Medline, and Web of Science were systematically searched without restrictions. We only used the standardized mean differences (SMD) with their 95 % confidence intervals (95 % CI) as the effect measure. A random-effects model (DerSimonian and Laird method) was used for the meta-analysis. Risk of bias was assessed with the Newcastle–Ottawa Scale and Newcastle–Ottawa Scale for Cross-Sectional Studies.</p></div><div><h3>Results</h3><p>Twenty-six studies (n = 3,787) were included in the meta-analysis. Participants with T2D had higher asprosin values than those without T2D (SMD: 1.64; 95 % CI: 1.08–2.21; I<sup>2</sup> = 97 %). Patients with MetS had higher asprosin levels compared to those without MetS (SMD: 0.99; 95 % CI: 0.34–1.64; I<sup>2</sup> = 96 %). Patients with obesity had higher asprosin levels than participants without obesity (SMD: 1.49; 95 % CI: 0.23–2.76; I<sup>2</sup> = 98 %).</p></div><div><h3>Conclusions</h3><p>Asprosin is significantly higher in patients with either T2D, MetS, or obesity, compared with controls.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103095"},"PeriodicalIF":4.3000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1871402124001565","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background & aims

Asprosin is a promising candidate for novel treatments for metabolic–endocrine disorders. The objective of this systematic review and meta-analysis was to consolidate the existing evidence regarding asprosin levels in patients diagnosed with type 2 diabetes (T2D), metabolic syndrome (MetS), and obesity.

Methods

Scopus, Embase, PubMed, Ovid/Medline, and Web of Science were systematically searched without restrictions. We only used the standardized mean differences (SMD) with their 95 % confidence intervals (95 % CI) as the effect measure. A random-effects model (DerSimonian and Laird method) was used for the meta-analysis. Risk of bias was assessed with the Newcastle–Ottawa Scale and Newcastle–Ottawa Scale for Cross-Sectional Studies.

Results

Twenty-six studies (n = 3,787) were included in the meta-analysis. Participants with T2D had higher asprosin values than those without T2D (SMD: 1.64; 95 % CI: 1.08–2.21; I² = 97 %). Patients with MetS had higher asprosin levels compared to those without MetS (SMD: 0.99; 95 % CI: 0.34–1.64; I² = 96 %). Patients with obesity had higher asprosin levels than participants without obesity (SMD: 1.49; 95 % CI: 0.23–2.76; I² = 98 %).

Conclusions

Asprosin is significantly higher in patients with either T2D, MetS, or obesity, compared with controls.

查看原文本刊更多论文

2 型糖尿病、代谢综合征和肥胖症患者体内的阿司匹林水平：系统回顾与荟萃分析。

背景和目的：阿司匹林是一种治疗代谢内分泌紊乱的新型候选药物。本系统综述和荟萃分析的目的是整合有关确诊为 2 型糖尿病（T2D）、代谢综合征（MetS）和肥胖症患者体内阿司匹林水平的现有证据：对 Scopus、Embase、PubMed、Ovid/Medline 和 Web of Science 进行了无限制的系统检索。我们仅使用标准化均值差异（SMD）及其 95 % 置信区间（95 % CI）作为效应测量指标。荟萃分析采用随机效应模型（DerSimonian 和 Laird 方法）。采用纽卡斯尔-渥太华量表（Newcastle-Ottawa Scale）和纽卡斯尔-渥太华横断面研究量表（Newcastle-Ottawa Scale for Cross-Sectional Studies）评估偏倚风险：荟萃分析纳入了 26 项研究（n = 3787）。患有 T2D 的参与者的asprosin值高于未患 T2D 的参与者（SMD：1.64；95 % CI：1.08-2.21；I2 = 97 %）。与非 MetS 患者相比，MetS 患者的asprosin 水平更高（SMD：0.99；95 % CI：0.34-1.64；I2 = 96 %）。肥胖症患者的asprosin水平高于非肥胖症患者（SMD：1.49；95 % CI：0.23-2.76；I2 = 98 %）：与对照组相比，患有 T2D、MetS 或肥胖症的患者体内的阿司匹林含量明显更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes & Metabolic Syndrome-Clinical Research & Reviews ENDOCRINOLOGY & METABOLISM-

CiteScore

22.90

自引率

2.00%

发文量

248

审稿时长

51 days

期刊介绍： Diabetes and Metabolic Syndrome: Clinical Research and Reviews is the official journal of DiabetesIndia. It aims to provide a global platform for healthcare professionals, diabetes educators, and other stakeholders to submit their research on diabetes care. Types of Publications: Diabetes and Metabolic Syndrome: Clinical Research and Reviews publishes peer-reviewed original articles, reviews, short communications, case reports, letters to the Editor, and expert comments. Reviews and mini-reviews are particularly welcomed for areas within endocrinology undergoing rapid changes.